10 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now
Small cap and mid cap stocks have been on a roll in the first half of the year as investors rotate away from mega cap tech stocks.
Sarepta Therapeutics Inc. (SRPT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 6,433,112 | $138,633,564 | -18% | 0.06% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 4,593,195 | $99,947,923 | +122% | 0.08% |
| 3. | RA Capital Management Peter Kolchinsky | 3,902,596 | $84,920,489 | 0.9% | |
| 4. | 57,306,000 | $54,727,230 | 1.77% | ||
| 5. | Renaissance Technologies Jim Simons | 1,665,078 | $36,232,097 | +44% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.66 | 5,648 | $760,559.68 | 284,034 | 2024-08-16 | Filing | |
| $134.06 | 18,284 | $2,451,153.04 | 278,386 | 2024-08-16 | Filing | |
| $133.07 | 13,106 | $1,744,015.42 | 260,102 | 2024-08-16 | Filing | |
| $78.81 | 40,000 | $3,152,400.00 | 140,000 | 2023-11-03 | Filing | |
| $78.81 | 10,000 | $788,100.00 | 10,000 | 2023-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.02 | 7,239 | $123,207.78 | 1,765 | 2026-03-12 | Filing | |
| $22.31 | 13,187 | $294,201.97 | 193,300 | 2025-12-16 | Filing | |
| $99.64 | 2,491 | $248,203.24 | 27,812 | 2025-03-12 | Filing | |
| $124.84 | 10,500 | $1,310,820.00 | 22,840 | 2024-12-12 | Filing | |
| $125.55 | 1,636 | $205,399.80 | 5,880 | 2024-12-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,755,277 | $321,074,830 | 0.01% | |
| 2. | 6,640,692 | $144,501,458 | 0% | |
| 3. | 6,613,314 | $143,905,713 | 0% | |
| 4. | 4,578,235 | $99,622,394 | 0% | |
| 5. | 4,135,788 | $89,994,703 | 0.06% |
News See All
15 Best Micro and Small Cap Stocks to Buy According to Jim Simons' Renaissance Technologies
The relief rally following the Iran-war-triggered sell-off has spread to small companies.
10 Best Gene Therapy Stocks to Buy in 2026
Gene therapies aim to treat or prevent diseases by introducing new instructions in a patient’s cells to fix or replace the defective genes behind genetic disorders.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to Sarepta Therapeutics, Inc.'s First Quarter 2026 Earnings Results Call. As a reminder, today's program is being recorded.
Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results
Sarepta Therapeutics soared by 34.98 percent on Wednesday to finish at $23.77 apiece, as investors took path from Morgan Stanley’s 25-percent price target upgrade for its stock following strong clinical...
10 Stocks Investors Are Buying Now: Chewy, Braze, Sarepta, and More
The company said that it has begun recruiting highly-skilled German talent to operationalize its upcoming satellite manufacturing facility in Berlin, as part of its plan to double the production capacity...
Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the best cheap biotech stocks to buy now. On February 27, Wells Fargo cut the price target on Sarepta Therapeutics, Inc.
12 Cheap Biotech Stocks to Buy Now
On February 27, Eli Casdin, Casdin Capital CEO, appeared on CNBC’s ‘Closing Bell’ to talk about the biotech sector.
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
We came across a bullish thesis on Sarepta Therapeutics, Inc. on 24K Research’s Substack. In this article, we will summarize the bulls’ thesis on SRPT.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2025 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2025 Earnings Call Transcript February 25, 2026Sarepta Therapeutics, Inc. misses on earnings expectations.
Hedge Fund Resource Center